Alto Neuroscience, Inc. (NYSE:ANRO) Receives $35.25 Average PT from Analysts

Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $35.25.

Several equities research analysts have weighed in on ANRO shares. Weiss Ratings raised Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. HC Wainwright reaffirmed a “buy” rating on shares of Alto Neuroscience in a research note on Wednesday, June 17th. JonesTrading dropped their target price on Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. Wall Street Zen downgraded Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research report on Sunday, May 17th. Finally, Bank of America initiated coverage on Alto Neuroscience in a report on Tuesday, May 5th. They set a “buy” rating and a $35.00 price target on the stock.

Get Alto Neuroscience alerts:

Read Our Latest Stock Report on Alto Neuroscience

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. lifted its stake in Alto Neuroscience by 14,567.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock worth $3,786,000 after purchasing an additional 211,222 shares during the last quarter. Artia Global Partners LP purchased a new position in shares of Alto Neuroscience during the fourth quarter valued at approximately $520,000. Perceptive Advisors LLC grew its stake in shares of Alto Neuroscience by 1,048.5% during the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after buying an additional 1,629,027 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of Alto Neuroscience during the first quarter valued at approximately $538,000. Finally, Spruce Street Capital LP bought a new position in shares of Alto Neuroscience during the fourth quarter valued at approximately $3,967,000.

Alto Neuroscience Trading Up 0.4%

ANRO stock opened at $27.91 on Thursday. The firm has a fifty day moving average price of $23.04 and a 200 day moving average price of $21.07. Alto Neuroscience has a fifty-two week low of $2.59 and a fifty-two week high of $28.85. The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52. The firm has a market cap of $979.19 million, a PE ratio of -11.53 and a beta of 1.04.

Alto Neuroscience (NYSE:ANRO – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). Sell-side analysts anticipate that Alto Neuroscience will post -3.01 earnings per share for the current fiscal year.

About Alto Neuroscience

(Get Free Report)

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

Featured Articles

• Five stocks we like better than Alto Neuroscience
• Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
• CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
• Why ASML’s AI Monopoly Is Still Getting Stronger
• Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings

Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.